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Abstract
Background: MicroRNA (miRNA)-mediated RNA silencing is integral to virtually every cellular process including cell
cycle progression and response to virus infection. The interplay between RNA silencing and HIV-1 is multifaceted,
and accumulating evidence posits a strike-counterstrike interface that alters the cellular environment to favor virus
replication. For instance, miRNA-mediated RNA silencing of HIV-1 translation is antagonized by HIV-1 Tat RNA
silencing suppressor activity. The activity of HIV-1 accessory proteins Vpr/Vif delays cell cycle progression, which is a
process prominently modulated by miRNA. The expression profile of cellular miRNA is altered by HIV-1 infection in
both cultured cells and clinical samples. The open question stands of what, if any, is the contribution of Tat RNA
silencing suppressor activity or Vpr/Vif activity to the perturbation of cellular miRNA by HIV-1.
Results: Herein, we compared the perturbation of miRNA expression profiles of lymphocytes infected with HIV-
1
NL4-3 or derivative strains that are deficient in Tat RNA silencing suppressor activity (Tat K51A substitution) or
ablated of the vpr/vif open reading frames. Microarrays recapitulated the perturbation of the cellular miRNA profile
by HIV-1 infection. The miRNA expression trends overlapped ~50% with published microarray results on clinical
samples from HIV-1 infected patients. Moreover, the number of miRNA perturbed by HIV-1 was largely similar
despite ablation of Tat RSS activity and Vpr/Vif; however, the Tat RSS mutation lessened HIV-1 downregulation of
twenty-two miRNAs.
Conclusions: Our study identified miRNA expression changes attributable to Tat RSS activity in HIV-1
NL4-3.T h e
results accomplish a necessary step in the process to understand the interface of HIV-1 with host RNA silencing
activity. The overlap in miRNA expression trends observed between HIV-1 infected CEMx174 lymphocytes and
primary cells supports the utility of cultured lymphocytes as a tractable model to investigate interplay between
HIV-1 and host RNA silencing. The subset of miRNA determined to be perturbed by Tat RSS in HIV-1 infection
provides a focal point to define the gene networks that shape the cellular environment for HIV-1 replication.
Background
MicroRNA (miRNA)-mediated RNA silencing is integral
to virtually every aspect of biology, including pluripo-
tency, development, differentiation, proliferation, and
antiviral defense [1-3]. The activity of miRNA has the
capacity to coordinate intricate gene expression net-
works [2]. Most coding genes exhibit one or many
miRNA recognition elements (MRE), and a single
miRNA may regulate dozens of genes in response to
viral infection or another environmental cue. The
mature miRNAs are processed from a primary transcript
to a precursor form that is subject to nuclear export. In
the cytoplasm, the activity of Dicer, Argonaute (Ago)
and TAR RNA-binding protein (TRBP) produces mature
miRNA, which is ~22 nt in length [4]. This ribonucleo-
protein complex (RNP) is loaded onto a multicompo-
nent RNA-induced silencing complex (RISC), and the
miRNA guides the interaction of RISC with one or
more partially complementary MRE. MRE interaction
with the cognate miRNA guide strand produces
sequence-specific RNA silencing by RISC. Virus modu-
lation of miRNA expression or RNA silencing activity
has the capacity to counteract antiviral restriction [5].
Collectively, viruses encode proteins and decoy RNAs
to counter innate restriction of endogenous and
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tions and miRNA-mediated RNA silencing is best
understood in plants. Plant miRNA activity provides a
robust antiviral host restriction that is countered by
plant virus-encoded RNA silencing suppressors (RSS)
that are necessary for viral pathogenesis [6]. RSS have
also been found in animal viruses [7], and the list of
human viruses that encode an RSS is growing [8]. RSS
activity is exhibited by multifunctional RNA binding
proteins encoded by ebolavirus [9,10], influenza virus
[11], and human T-cell lymphotropic virus type 1 [12].
In the case of ebolavirus, RNA silencing suppressor
activity is exhibited by three viral proteins (VP30, VP35,
VP40), which suggests an effective counter strike to the
small RNA-based host defense is under strong positive
selection [10]. Adenovirus expresses abundant levels of
VA1 RNA that saturates pre-miRNA nuclear export and
pre-miRNA processing to potently reduce miRNA pro-
duction [13]. In contrast to the generalized downregula-
tion of RNA silencing by VA1, the activity of viral RSS
proteins on protein effectors of RNA silencing activity is
subtle and conceivably may target a subset of miRNA
[6,8,14,14].
Several lines of evidence indicate that small RNA
activity is important for HIV-1. Cell-encoded miRNA
attenuate virus replication in activated T lymphocytes
[15] and in latently infected resting T lymphocytes [16].
HIV-1 mRNA translation is attenuated by RNA silen-
cing [14], and HIV-1 mRNAs associate and co-localize
with components of the RISC [17]. Downregulation of
RNA silencing effectors (RCK/p54 or DGCR8) in
PBMCs of HIV-1 infected patients on HARRT results in
virus reactivation [17]. While RISC activity suppresses
HIV-1 replication in at least some circumstances, the
small RNA pathway appears to be harnessed to alter cel-
lular gene expression to foster virus replication [18-20].
HIV-1-encoded RNA silencing suppressor activity has
been controversial, given differences in experimental
conditions [21,22]. Consensus is emerging of an intricate
and multifaceted relationship between the human
miRNA-mediated silencing pathway and HIV-1 [23] that
operates in a strike-counterstrike manner [24]. A cor-
nerstone of this complex relationship is the essential
viral transcriptional trans-activator Tat and its cis-acting
trans-activation responsive element, TAR. TAR is a
structured RNA element within the 5’ terminus of all
HIV-1 transcripts that forms a stem-bulge-stem RNA
structure that is recognized by Tat and cellular factors
TRBP and P-TEFb to robustly activate productive viral
gene transcription. Bennasser and colleagues identified
RSS activity in Tat that requires the arginine-rich dou-
ble-stranded RNA binding domain [21]. Tat RSS activity
is genetically separable from Tat transcriptional activity
by K51A substitution in the double-stranded RNA
binding domain [21]. HIV-1 Tat functions across the
plant and animal kingdoms to suppress a common step
in RNA silencing that is downstream of small RNA
maturation [14]. Translation of virion structural protein
is exacerbated by K51A substitution in the Tat RNA
binding domain (HIV-1
NL4-3RSS) [14]. The delay in
HIV-1 replication by Tat K51A substitution can be
complemented by TBSV P19 [14] and rice hoja blanca
virus non-structural protein 3 (NS3) [25]. Thus, virus
interplay with miRNA-mediated RNA silencing is con-
served across the plant and animal kingdoms, and Tat
RSS activity is important in biology of the human retro-
virus, HIV-1.
The potential for RSS activity by TAR RNA was initi-
ally identified by Bennasser and colleagues [26]. Similar
in principle to adenovirus VA1 RNA, TAR squelches
the activity of host protein required for RNA silencing
activity. In cells transfected with TAR RNA, TAR acts
to occlude TRBP from Dicer and thereby interferes with
dsRNA-processing [26]. TAR interaction with TRBP
exerts several activities in HIV-1 biology [27-30]. TRBP
was originally identified in a cDNA screen for proteins
necessary for TAR/Tat transcriptional trans-activation
[31,32]. Subsequently, TRBP was identified to inhibit the
activity of protein kinase R (PKR) that is directed to
double stranded features of viral RNA [33]. The poten-
tial for TAR to sequester TRBP and downregulate
miRNA maturation or RISC activity [26] is attributable
to structural features of the HIV-1 RNA that are pro-
cessed to viral miRNA [18-20] or to early HIV-1 viral
transcripts that are prematurely terminated [34]. In sum,
Tat and TAR have the potential to manipulate the RNA
silencing pathway in a strike-counter-strike manner
[23,24]. The resulting alteration of the cellular environ-
ment may tip the balance to favor virus replication or
favor viral latency. The identification of the miRNA
affected by HIV-1 RSS activity and future determination
of the MRE targeted by these miRNA, are strategic mile-
stones in the process to understand the viral interface
with host RNA silencing.
MiRNAs contribute to physiological control of the cell
cycle [35]. Hsa-miR-17-5p modulates the G1/S transi-
tion by targeting over twenty genes that regulate pro-
gression of the cell cycle [36]. The broadly conserved
miRNA let-7 family controls exit from the cell cycle in
Caenorhabditis elegans [37]. Human fibroblasts arrest in
G2/M by overexpression of let-7 family members [38].
In human cancers, tumor progression is attributable to
dysregulation of cell cycle control by miRNA [39,40].
G2/M delay is a feature of HIV-1 infected cells that is
attributable to the HIV-1 accessory proteins Vpr and Vif
[41-43]. Ablation of vpr/vif restores cell cycle profiles to
be similar to uninfected cells [43]. A primary role for
Vpr is to trans-activate viral gene expression during
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Vif is to combat antiviral restriction by APOBEC pro-
teins [46,47]. Vif additionally contributes to downregula-
tion of Vpr, which would reduce transcription trans-
activation [48]. The possibility remains to be addressed
that Vpr and Vif contribute to perturbation of cellular
miRNA by HIV-1, perhaps by trans-activation. A neces-
sary step in the process to understand interplay of the
virus with host RNA silencing is the definition of
miRNA expression differences during infection with
HIV-1 or Vpr/Vif-deficient HIV-1.
Herein, we have evaluated the perturbation of miRNA
signature of cultured lymphocytes by HIV-1 and HIV-1
derivatives deficient in Vpr/Vif (ΔVV) or Tat RSS (RSS).
Our results indicate that the miRNA signature is per-
turbed by HIV-1 infection, and a subset of miRNA is
differentially expressed by elimination of the HIV-1 Tat
RNA silencing antagonist. Additionally, we observed
~50% overlap between the miRNA signatures of cul-
tured lymphocytes infected with HIV-1 and clinical sam-
ples from HIV-1 infected individuals. The outcomes are
a list of candidate miRNAs that interface with cellular
genes important to HIV-1 replication, and a tractable
model to investigate the interplay between HIV-1 and
cellular miRNA that alters the cellular environment dur-
ing virus infection.
Results
Comparison of miRNA expression profiles produced by
HIV-1 and strains deficient in Tat RSS or Vpr/Vif
Three strains of HIV-1
NL4-3 were propagated by trans-
fection of provirus (Figure 1) into HEK293 cells, and
cell-free virus was used to generate HIV-1/CEMx174
lymphocytes. HIV-1 infection by cell-free HIV-1 is rela-
tively inefficient unless enhanced by spinoculation
[49,50], whereas HIV-1 infection by co-culture is effi-
cient [51]. All experiments were carried out by co-cul-
ture infection of CEMx174 lymphocytes to minimize the
confounding signal from uninfected cells. We monitored
the progression of the infection by FACS of intracellular
Gag at several intervals. The benchmark criterion for
lymphocyte harvest was set at ≥80% infection in order
to minimize the background signal from residual unin-
fected cells. Comparison of HIV-1
NL4-3 to the derivative
strains ΔVV and RRS revealed differences in replication
kinetics, similar to previous observations [21,52]. The
FACS of intracellular Gag at ~12 h intervals determined
that HIV-1
NL4-3 and ΔVV reached ≥80% infection by 40
to 48 hr, while RSS reached ≥80% infection by 60 hr
(Table 1). Cell viability was monitored by trypan blue
exclusion and was determined to be ≥90% at time of
harvest. Total cellular RNA was harvested from replicate
infections and subjected to bioanalyzer analysis to verify
integrity. The RNA samples were treated with reverse
transcriptase and random hexamer primer, and biotiny-
lated cDNA was generated for hybridization by the
miRNA microarray shared resource of the Ohio State
University Comprehensive Cancer Center. Two replicate
experiments used miRNA microarray chips printed with
906 duplicate probes that measure levels of 518 mature
miRNA and 332 precursor miRNA [53]; four probes
were excluded because they have been deleted from
miRBase. Signal intensity from two independent infec-
tions per virus was quantified with GenePix Pro 6 image
analysis software, and the data were evaluated for back-
ground correction, log base 2 transformation, and quan-
tile normalization. Microsoft Excel pivot tables were
used to manage comparative expression trends for viral
strains. Signal intensities in log2 values ranged from 0.3
to 16.0; and a signal intensity of log2 value of 5 or
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Figure 1 Host miRNA expression levels were compared
between HIV-1
NL4-3, Vif/Vpr-deficient or Tat K51A RSS-deficient
strains. CEMx174 lymphocytes were infected by co-culture with
HIV-1
NL4-3, HIV-1
NL4-3 ΔVV that contains a premature stop codon in
vif and frameshift in vpr, or HIV-1
NL4-3 RSS that contains the K51A
substitution that eliminates Tat RSS activity. Total cellular RNA was
reverse transcribed and hybridized to miRNA microarray chips with
two or three independent biological replicates to determine relative
expression levels of 518 mature miRNA and 336 precursor miRNA
that were monitored by 906 human miRNA probes spotted in
duplicate [53].
Table 1 Percentage of CEMx174 infected cells at time of
RNA harvest
Percentage of Virus Infected Cells
a
Experiment Mock HIV-1 RSS ΔVV
Replicate 1 0 90 83 80
Replicate 2 0 95 87 90
a CEMx174 cells were infected by co-culture and the progression of infection
was monitored by FACS of intracellular Gag. Values indicate the percentage of
Gag
+ cells at time of harvest. Total cellular RNA was prepared in Trizol,
integrity verified by bioanalyzer and processed for the miRNA microarrays.
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Signal intensities in log2 values greater that 16 corre-
sponded to saturation of signal. MiRNA expression was
considered changed if upregulated 2-fold or downregu-
lated by a factor of 2 or more. Four categories of
miRNA expression were enumerated: Up; Down; No
change (levels remained within a factor of 2 of unin-
fected control); or Less than the minimum detectable.
The miRNA signature is perturbed by HIV-1 and
derivatives deficient in vpr/vif or Tat RSS
HIV-1 perturbed the expression of ~200 of the 518
mature miRNAs on the chip; ~70 miRNAs were upregu-
lated and ~100 miRNAs were downregulated (Table 2).
The number of up- or down-regulated miRNAs was
similar between HIV-1
NL4-3, ΔVV and RSS (Table 2).
Scatterplot analysis of the expression changes relative to
mock infection revealed the range of expression differ-
ences was similar among the infections (Figure 2). Fifty-
two miRNAs were upregulated by all three strains, and
eighty-three miRNAs were downregulated by all three
strains.
We examined the data for miRNAs that exhibited ≥2-
fold expression change between the viral strains. As
shown in scatterplot analysis between HIV-1 and ΔVV,
five miRNAs fall outside the two-fold change lines (Fig-
ure 3); HIV-1 exhibited ≥2-fold greater expression of
hsa-miR-32, hsa-miR-194, hsa-miR-199a, hsa-miR-496,
and expression of hsa-miR-450 was reduced. The results
indicate that ablation of vif/vpr modestly alters miRNA
profile. We expected this minor difference is attributable
to experimental variation, and this issue would be
resolved by additional experiments. By comparison, the
scatterplot analysis unveiled nineteen miRNAs that
exhibited expression differences between HIV-1 and
RSS (Figure 3, Table 3). The results indicate that pertur-
bation of the cellular miRNA signature by HIV-1 infec-
tion is largely independent of the activity of vpr/vif or
Tat RSS.
Tat RSS mutation affects the steady state of a subset of
miRNA
HIV-1 exhibited 2 to 3-fold greater expression of fifteen
miRNA relative to RSS (Table 3). Four miRNA were
downregulated in HIV-1 relative to RSS by a factor of 2
Table 2 Distribution of changes in mature miRNA
expression relative to uninfected lymphocytes for
infection with indicated viral strain
Infection Relative to Mock
a
Expression Trend
b HIV-1 RSS ΔVV
Up 72 74 74
Down 106 104 111
No change 157 153 146
<MD 234 238 238
a Human CEMx174 lymphocytes infected by co-culture with indicated virus
were screened by miRNA microarray. The number of mature miRNA probes
present on the chip was 518 after exclusion of four probes removed from
miRBase. Values represent number of probes affected.
b Up: upregulated (≥2.0
×); Down: downregulated (≤0.5×); No change: between 0.5-2.0 ×; <MD: less
than minimum detectable limits.
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Figure 2 Host miRNA expression is changed by infection with
HIV-1, Vif/Vpr -deficient or RSS-deficient viral strains. Scatterplot
analysis of miRNA mature and precursor probes expression changes
observed on microarrays hybridized with RNA of human CEMx174
lymphocytes unexposed to virus or infected with HIV-1, or ΔVV, or
RSS. Each data point represents one unique probe sequence. The
black line at x = y illustrates baseline of no change. The red lines
illustrate change by a factor of 2. Axes are truncated at log2 =5t o
eliminate measurement uncertainty at lower signal intensities. Log2
expression values of human miRNA probes in the mock sample are
shown on the x-axis and the corresponding values for the HIV-1
sample are shown on the y-axis. (a) HIV-1 versus mock infection; (b)
RSS versus mock infection; (c) ΔVV versus mock infection.
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Page 4 of 13to 4 (Table 3). Of the 145 miRNA perturbed by the
three viral infections relative to cells without virus infec-
tion (mock), Tat RSS activity in HIV-1 correlated with
higher steady state for 15 of the 18 and lower steady
state for 3 miRNA (Table 4). These differences may be
attributable to direct effects of Tat RSS activity on RNA
stability or by secondary effects elicited through
upstream genes. In sum, the observed generalized per-
turbation of miRNA expression by HIV-1 infection of
cultured lymphocytes is consistent with previous micro-
arrays of HIV-1 infected cells [15,54,55]. The compari-
son of the three derivative viruses determined that the
generalized perturbation of miRNA expression levels by
HIV-1 is largely independent of the ablation of Vpr/Vif
and Tat RSS.
The miRNA that were downregulated by all three viral
infections (n = 83) were filtered to ascertain possible dif-
ferences in the level of downregulation. Twenty-two
miRNA exhibited less downregulation by 10% or more
in RSS compared to HIV-1 or ΔVV infection (p =
≤0.0001) (Table 5). Subsequent investigations are war-
ranted to evaluate the possibility that these miRNA have
conserved features and to determine the MRE that are
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Figure 3 Ablation of Tat RSS alters miRNA expression trends
relative to HIV-1 and Vif-/Vpr-deficient HIV-1. Scatterplot analysis
of miRNA mature and precursor probes expression changes
observed on microarrays hybridized with RNA from human
CEMx174 lymphocytes infected with HIV-1, ΔVV, or RSS. Log2
expression values of human miRNA probes in the HIV-1 infections
are shown on the y-axis, log2 expression values for miRNA probes in
either RSS or ΔVV infection are shown on the x-axis. (a) HIV-1 versus
ΔVV infection; (b) HIV-1 versus RSS infection.
Table 3 Mature miRNAs that exhibit expression change
by a factor of ≥2 for RSS relative to HIV-1 infection
MiRNAs differing in expression by ≥2 between RSS and HIV-1
MiRNA Probe Ratio RSS/HIV-1
Upregulated
hsa-miR-105 2.1
hsa-miR-550 2.1
hsa-miR-32 2.2
hsa-miR-33b 2.2
Downregulated
hsa-miR-30e-3p 0.3
hsa-miR-194 0.3
hsa-miR-494 0.3
hsa-miR-500 0.3
hsa-miR-20a 0.4
hsa-miR-20b 0.4
hsa-miR-21 0.4
hsa-miR-26b 0.4
hsa-miR-106a 0.4
hsa-miR-215 0.4
hsa-miR-219 0.4
hsa-miR-453 0.4
hsa-miR-17-5p 0.5
hsa-miR-499 0.5
hsa-miR-658 0.5
Table 4 Mature miRNAs that exhibit expression change
by a factor of ≥2 between RSS and HIV-1 infection
standardized to mock
RSS Relative to Mock
a
Up Unchanged Down
Up hsa-miR-494 hsa-miR-194
hsa-miR-500
-
Relative Unchanged - hsa-miR-33b
hsa-miR-105b
hsa-miR-453
hsa-miR-499
hsa-miR-17-5p
hsa-miR-20a
hsa-miR-20b
hsa-miR-30e-3p
hsa-miR-106a
hsa-miR-219
Mock Down - - hsa-miR-21
hsa-miR-26b
hsa-miR-32
hsa-miR-215
hsa-miR-658
a Nineteen miRNAs exhibited expression differences between the indicated
strains relative to mock infection. The miRNAs indicated in plain font
exhibited reduced expression by a factor of 2 or more for RSS compared to
HIV-1. The three miRNAs in underlined font exhibited increased expression by
2-fold or more for RSS compared to HIV-1. Notably, miR550 upregulation by
HIV-1 was attenuated in RSS infection (Table 3) but is excluded from Table 4
because miR550 was not detectable in cells lacking virus (mock infection).
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with removal of RSS activity that affects the steady state
of this subset of miRNA.
Comparison of miRNA expression trends in clinical
samples and cultured lymphocytes
The microarrays are useful to gauge expression trends
but RT-quantitative PCR (qPCR), and other more sen-
sitive and specific assays are required to quantify
expression differences [53,56]. For independent assess-
ment of the miRNA expression trends, we performed
RT-qPCR with Taqman miRNA assays. We evaluated
hsa-miR-29a, hsa-miR-198, hsa-miR-128, hsa-miR-214
because they are reported to target HIV-1 or to pos-
sess antiviral activity [57,58]. The snoRNA RNU48
provided an internal control that has been useful in
qPCR analysis of miRNA [59,60]. A series of dilution
curves determined the efficiency of each Taqman
probe (data not shown), and the expression changes
were determined in RNA samples from HIV-1, ΔVV
and RSS infections and uninfected lymphocytes (Mock)
from independent replicate infections. Triplicate assays
were performed, and miRNA levels were quantified
with efficiency correction; and the data are presented
relative to the internal control RNU48. Results are
expressed as fold change relative to the mock control
by the ΔΔCT method [61].
The upregulation of hsa-miR-214 and hsa-miR-198
by the three virus strains was confirmed by RT-qPCR
(Table 6). The qPCR measured greater upregulation
(8-fold) than the microarray (2-fold), consistent with
greater sensitivity for the Taqman probes relative to
the hybridization probes. Hsa-miR-214 is reported to
exhibit broadly active antiviral activity [57], and hsa-
miR-198 has been shown to target cyclin T1, a host
cellular protein necessary for Tat transcriptional trans-
activation [62]. Over expression of hsa-miR-198 has
been shown to reduce HIV-1 gene expression and
replication [62]. Therefore, the observed upregulation
would be expected to deter viral replication. The
Table 5 Downregulation of selected miRNAs is diminished by RSS mutation
Downregulation Relative to Mock Infection
a Lessened Downregulation for RSS Relative to Indicated Infection
b
miRNA HIV-1 RSS ΔVV HIV-1 ΔVV
hsa-miR-10a 26% 43% 32% 17% 10%
hsa-miR-23a 19% 34% 22% 15% 11%
hsa-miR-25 27% 43% 15% 17% 28%
hsa-miR-27a 31% 37% 18% 6% 19%
hsa-miR-30d 34% 54% 30% 20% 25%
hsa-miR-32 11% 24% 4% 13% 19%
hsa-miR-92 33% 50% 33% 17% 17%
hsa-miR-95 39% 51% 41% 12% 10%
hsa-miR-99b 46% 53% 33% 7% 20%
hsa-miR-100 24% 35% 19% 11% 16%
hsa-miR-103 46% 53% 37% 6% 16%
hsa-miR-107 42% 51% 31% 8% 20%
hsa-miR-125b 16% 26% 19% 10% 7%
hsa-miR-128 26% 47% 29% 21% 19%
hsa-miR-135a 23% 35% 18% 12% 17%
hsa-miR-142-5p 24% 30% 20% 5% 10%
hsa-miR-148b 37% 49% 39% 12% 10%
hsa-miR-181a 40% 53% 47% 13% 6%
hsa-miR-186 50% 64% 50% 14% 14%
hsa-miR-193a 40% 69% 44% 29% 24%
hsa-miR-369-3p 27% 41% 39% 14% 2%
hsa-miR-376a 43% 59% 43% 16% 15%
hsa-miR-379 40% 61% 47% 21% 14%
hsa-miR-423 44% 65% 24% 21% 41%
hsa-miR-601 31% 38% 21% 7% 17%
hsa-miR-660 40% 66% 42% 26% 24%
hsa-miR-671 36% 47% 46% 11% 0
a Expression trend compared to uninfected CEMx174 lymphocytes (Mock). Bold designates miRNAs downregulated in PBMC of HIV-1 patients [55].
b Percentage increase between RSS relative to indicated strain.
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context of HIV-1 infected CD4
+ T cells will be an
important followup study.
The downregulation of hsa-miR-128 was not recapitu-
lated by the RT-qPCR assay and the levels of hsa-miR-
29a were downregulated, but less than the 2-fold cutoff
(Table 6). The signal intensities measured for these
miRNA by qPCR and the microarray were within nor-
mal ranges for detection. We expect the discrepancy is
attributable to differences in microarray probe efficiency
relative to qPCR. We repeated the qPCR with primers
that amplify the precursor miR-29a and observed down-
regulation by a factor of 2 for the pre-miRNAs (data not
shown), which is consistent with reduced expression.
Microarrays by Houzet et al. [55] identified hsa-miR-29a
downregulation in HIV-1 infected lymphocytes, consis-
tent with the trends in our microarrays. These results
emphasize the utility of microarrays to screen for differ-
ences in expression and that more sensitive and specific
approaches are required to quantify expression differ-
ences. Because microarray studies have been used to
assign HIV-1 miRNA expression signatures in a variety
of cultured cells and clinical specimens, we investigated
their overlap with the HIV-1 miRNA expression signa-
tures in our study.
We evaluated our datasets against a published miRNA
microarray analysis of patient samples to identify
miRNA expression changes, if any, that are sustained
among the HIV-1 infection models. Houzet et al. stu-
died a cohort of twelve uninfected controls and thirty-
six HIV-1 infected patients, who were stratified into
four groups by CD4+ T cell count and viral load [55].
Microarray analysis of PBMC identified sixty-two
miRNA that were modulated relative to the uninfected
cohort. The criteria for differential expression was a
change by a factor of 2 or more in >50% of patients in
at least one of four different groups. Additionally, sam-
ples of naive PBMC were infected with HIV-1
NL4-3 or
treated with anti-CD3 to activate T cells and subjected
to miRNA microarray. The results identified an addi-
tional thirty-one miRNA probes with expression
modulation by a factor of 2 or more in at least one of
these samples. These miRNAs were represented by
probes in our microarray analyses, although twenty-four
exhibited signal intensities below minimum detectable
limits (Figure 4, designated in italics).
Of the sixty-two miRNAs with modulated expression
in HIV-1 infected patients, thirty-three exhibited simi-
lar change in expression in CEMx174/HIV-1
NL4-3 (Fig-
ure 4) and CEMx174/RSS and CEMx174/ΔVV (data
not shown). Of these, thirty-two miRNAs exhibited
downregulation (designated in blue). One miRNA was
upregulated in both the patient dataset and in
CEMx174/HIV-1
NL4-3 (designated in red). Thirteen
miRNAs that exhibited expression modulation in the
patient dataset were unchanged in CEMx174/HIV-
1
NL4-3 (Figure 4, miRNAs in plain font that are
excluded from CEMx174/HIV-1
NL4-3). Fourteen miR-
NAs present in patients were below detectable limits
in CEMx174/HIV-1
NL4-3 (Figure 4, italics). A reversed
expression trend was observed for hsa-miR-150 and
hsa-miR-337 (Figure 4, underline), which were downre-
gulated in patient PBMC and upregulated in
CEMx174/HIV-1
NL4-3. Six instances of reversed
expression trend (Figure 4, underline) were observed
between naive PBMC/HIV-1
NL4-3 and CEMx174/HIV-
1
NL4-3. Overall, there was approximately 50% overlap
between CEMx174/HIV-1
NL4-3 and patient samples.
Houzet et al. had observed similar overlap in their
comparison of naive PBMC/HIV-1
NL4-3 and uninfected
activated T cells [55]. We consider the 50% overlap
between CEMx174/HIV-1
NL4-3 and patient samples to
be appreciable given the differences in cell lineage,
infection parameters and the admixture of uninfected
cells in blood samples from patients [63]. We speculate
that the overlap identified with patient PBMCs, despite
the admixture with uninfected cells, is attributable to
paracrine signaling or another bystander effect that is
not solely seen by T cell activation. The results sup-
port the utility of the cultured lymphocytes as a valid
model to refine experimental design and interpretation
of data from patient samples.
Table 6 Comparison of expression trends identified by microarray or RT-qPCR in independent RNA preparations
Expression Trend in Microarrays Expression Relative to Mock Measured by qPCR
a
HIV-1 RSS ΔVV
Upregulated
hsa-miR-198 8.3 ± 1.0 8.3 ± 2.2 9.5 ± 0.3
hsa-miR-214 8.6 ± 4.5 15.3 ± 5.4 12.7 ± 5.7
Downregulated
hsa-miR-29a 0.8 ± 0.1 0.6 ± 0.1 1.0 ± 0.3
hsa-miR-128 1.1 ± 0.4 1.0 ± 0.2 0.9 ± 0.1
a Change in expression for indicated miRNAs was measured by qRT-PCR using Taqman probes in independent RNA preparations of HIV-1, RSS, ΔVV, and mock
infected cells. Values for quantitative RT-PCR are derived from at least three replicate experiments, and expressed relative to mock. Relative expression
differences were calculated using the ΔΔCT method with efficiency correction and RNU48 as the internal control.
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Page 7 of 13Figure 4 Venn diagram determined overlap between cli n i c a la n dc u l t u r e dH I V - 1i n f e c t e dc e l l s . Venn diagram integrating miRNA
expression trends from four datasets that are designated by labeled oval: CEMx174/HIV-1
NL4-3 (this study); primary PBMC/HIV-1
NL4-3; uninfected T
cells activated with anti-CD3; and PBMC of HIV-1 infected patients [55]. MiRNA upregulated by ≥ 2 are designated in red; miRNA downregulated
by a factor of ≥2 are designated in blue; miRNA designated by underscore exhibit discordant expression in CEMx174/HIV-1
NL4-3. Asterisk: miRNA
nomenclature designating the less abundant product of a precursor hairpin [69].
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Removal of Tat RSS activity affects expression of a subset
of miRNA
This study determined that perturbation of miRNA
expression by HIV-1 is largely independent of vif/vpr
and Tat RSS activity in culture lymphocytes. One-hun-
dred and forty-five miRNA were perturbed by infection
with HIV-1
NL4-3, the Tat RSS-deficient derivative, and
the vif/vpr-deficient derivative. Eighty-three miRNA
were downregulated and ablation of the HIV-1 Tat
RNA silencing suppressor (K51A) lessened the downre-
gulation of twenty-two miRNA (p = ≤0.0001) (Table 5).
T h eR S Sa c t i v i t yo fT a tr e q u i r e st h eR N Ab i n d i n g
domain and in transfected cells functions at a late step
in the RNA silencing pathway after miRNA maturation
[14]. We also previously determined that HIV-1 Tat RSS
activity is functionally interchangeable with TBSV P19
in animal cells and in plant cells [14]. The crystal struc-
ture and biochemical analysis of TBSV P19 have deter-
mined the P19 RNA binding domain recognizes selected
small RNAs by their particular structural features [64].
By analogy, Tat recognizes TAR RNA by structural fea-
tures that resemble miRNA duplex regions. Conceivably,
a pseudo-TAR-Tat interaction poses as a decoy sub-
strate for TRBP that suppresses localized RNA silencing
activity [26]. Herein, the complex is inaccessible for
R I S Cl o a d i n go ri na na b e r r a n tR I S C .T h ea b e r r a n t
RISC might irreversibly capture the miRNA in cognate
MREs. Structural predictions posited in MirBase of sev-
eral miRNAs differentially regulated by RSS exhibit a U-
bulge feature that resembles TAR. We speculate that
Tat RSS activity on selected cellular miRNA is a fortui-
tous outcome of a structural resemblance to TAR,
which spares RNA silencing of their cognate MREs.
Future analysis of such a TAR-mimic hypothesis and
determination of the MRE of the miRNA modulated by
Tat RSS are necessary steps in the process to under-
stand the complex interface of HIV-1 with host RNA
silencing activity.
The explanations for perturbation of miRNA expres-
sion levels include a primary effect of HIV-1 on the sta-
bility of the miRNA or secondary effect on the
expression of the miRNA locus. A recent study of the
fate of miRNA subsequent to MRE regulation using an
inducible expression system determined that productive
interaction of miR223 with cognate MRE accelerates the
rate of decay of the miRNA [65]. A corollary scenario is
that HIV-1 Tat RSS sequesters the miRNA from pro-
ductive interaction with cognate MRE and indirectly
slows the miRNA’s rate of decay. Consistent with this
possibility, 15 of the 19 miRNAs differentially expressed
in HIV-1 versus RSS exhibited greater abundance in the
HIV-1 infection (Table 3). Comparison of miRNA
trends relative to mock infection revealed 6 of the 11
miRNAs downregulated in RSS possessed unchanged
expression in HIV-1 infection, and 2 of the 6 miRNAs
with expression unchanged in RSS infection were upre-
gulated in HIV-1 infection (Table 4). Future studies are
warranted to determine the biophysical mechanism for
Tat RSS interaction with selected miRNA, to measure
the stability of the miRNA subject to Tat RSS activity,
and the efficiency of the cognate MRE recognition and
regulation.
Little change in miRNA profile is observed by ablation of
Vpr/Vif
The possibility that HIV-1 manipulation of host
miRNA contributes to HIV-1 induced cell cycle delay
was posited by the prominent role of miRNA in cell
cycle progression. Of particular interest are the let-7
family members, whose role in cell cycle progression is
broadly conserved from Caenorhabditis elegans to
human [37,38]. Overexpression of let-7 family mem-
bers leads to G2/M arrest in human fibroblasts [38].
Furthermore, hsa-miR-21 modulates cell cycle through
regulation of BTG family member 2, a transcriptional
coregulator of the cyclin D1 promoter that is dysregu-
lated in laryngeal cancer [39]. Hsa-miR-15a and hsa-
miR-16 regulate the cell cycle and are downregulated
or deleted in some non-small cell lung tumors [40].
Expression differences were n o to b s e r v e df o rh s a - m i R -
16 or has-miRNA-15a in our analysis of HIV-1 and
Vpr/Vif-deficient HIV-1. Hsa-miR-17-5p, which is sup-
pressed by HIV-1, modulates the G1/S transition by
targeting over 20 genes that regulate progression of
the cell cycle [36]. An additional role for hsa-miR-17-
5p is regulation of the Tat transcriptional cofactor
PCAF [15,66]. Therefore downregulation of hsa-miR-
17-5p expression by HIV-1 would be expected to pro-
duce pleiotropic effects that emanate from increased
viral gene transcription. Hsa-miR-17-5p is downregu-
lated by a factor of 2 in HIV-1 infected CEMx174 cells
and downregulation in ΔVV is similar, suggesting Vif/
Vpr expression does not alter expression of this
miRNA. Our assessment determined that expression of
several let-7 family members is perturbed by HIV-1
with overlap displayed between CEMx174/HIV-1 infec-
tions and cultured lymphocytes, patient PBMC and
activated T cells (Figure 4). In each case, the expres-
sion trends were similar between HIV-1 and ΔVV. In
conclusion, our results did not unveil an effect of abla-
tion of vpr/vif on these miRNA that affect cell cycle
progression. The possibility remains that other HIV-1
gene products or miRNA feedback loops for cell cycle
progression contribute to HIV-1 induced G2/M delay
in lymphocytes.
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Page 9 of 13Trends overlap between infection models for several
miRNAs known to affect HIV-1 replication
We observed the perturbation of eight miRNAs known
t op l a yar o l ei nH I V - 1i n f e c t i o n( T a b l e7 ) .T h e s em i R -
NAs target HIV-1 mRNA or host genes required for
virus replication. Two members of the hsa-miR-17/92
cluster, hsa-miR-17-5p and hsa-miR-20a, target the
mRNA of the PCAF cofactor of Tat trans-activation.
Our results and published microarrays agree in down-
regulation of these miRNA by HIV-1 [54,55]. Their
perturbation in HIV-1 infection is near the 2-fold cut-
off and sensitive, and specific measurement of the
expression changes by RT-qPCR is warranted. Hsa-
miR-20a is downregulated by a factor of two or greater
in patient samples, infected PBMCs, and anti-CD3 acti-
vated T cells (Figure 4). In the study by Houzet et al.
[55], hsa-miR-17-5p reached significant downregulation
solely in anti-CD3 activated T cells (Figure 4). In
CEMx174/HIV-1 and CEMx174/ΔVV, hsa-miR-20a
was downregulated by a factor of 1.8 and 2, respec-
tively; and hsa-miR-17-5p was downregulated by a fac-
tor of 2 and 1.9, respectively. Further experiments are
warranted to measure the possible upregulation of
PCAF and other target genes. The observed downregu-
lation of hsa-miR-17-5p and hsa-miR-20a was greater
in CEMx174/RSS compared to HIV-1 (factor of 4).
Quantitative measurement by qPCR is necessary to
investigate the possibility that Tat RSS fosters a posi-
tive feedback loop for expression of PCAF. On the
other hand, the level of hsa-miR-198, which targets
cyclin T1 [62], is upregulated by all three HIV-1
NL4-3
strains tested in this study. Cyclin T1 also acts as a
cofactor for Tat transcriptional trans-activation, and
upregulation of hsa-miR-198 could reduce cyclin T1
levels. The impact on HIV-1 transcription activity
remains to be determined and consider in relation to
the contributions of cell lineage and activation status.
Conclusions
HIV-1
NL4-3 perturbs the miRNA expression profile of
CEMx174 lymphocytes. The removal of Tat RSS activity
from HIV-1 did not globally affect miRNA level, but
relaxed the downregulation of a subset of miRNA.
Broad similarities in miRNA expression trends were
observed in HIV-1
NL4-3 infected CEMx174 cells and
clinical samples from HIV-1 infected patients [55]. The
overlapping trends validate that cultured lymphocytes
provide a tractable model to develop specific hypotheses
of interplay between HIV-1 and miRNA-mediated RNA
silencing that inform translational investigations in clini-
cal specimens. The determination that Tat RSS activity
affects the expression level of a subset of miRNAs is a
necessary step in the process to understand the interface
of HIV-1 with host RNA silencing activity. The miRNAs
we have determined to be dysregulated by Tat RSS in
HIV-1 infected lymphocytes provide a focal point to the
MRE and target genes that shape the cellular environ-
ment in HIV-1 infection.
Table 7 Cellular miRNAs with published effect on HIV-1 exhibited similar expression trends between indicated
infections of CEMx174 lymphocytes
Expression Level for
Indicated Infection State Relative to Mock
a
miRNA HIV-1 RSS ΔVV Targeted Transcript
and Expected Outcome
hsa-miR-17-5p 0.5 0.3 0.4 3’-UTR PCAF
(Triboulet 2007 [15])
hsa-miR-20a 0.6 0.2 0.5 Upregulation of cofactor
for Tat transcriptional
trans-activation, PCAF
hsa-miR-150 2.1 2.7 1. 8
hsa-miR-382 1.7 1.1 1.4 HIV-1 3’-UTR
hsa-miR-125b 0.2 0.3 0.2 (Huang 2007 [16])
Promotion of viral latency
hsa-miR-28 <MD <MD <MD in resting T cells
hsa-miR-223 <MD <MD <MD
hsa-miR-198
b 2.1 1.7 2.1 3’-UTR CCNT1
(Rice and Sung 2009 [62])
Downregulation of
cofactor for Tat
transcriptional trans-
activation, cyclin T1
a Expression trends of indicated cellular miRNAs given for each viral strain relative to uninfected controls.
b <MD: less than the minimum detectable signal.
c Upregulation trend was validated by qRT-PCR on independent infections.
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Proviruses and cells
HIV-1 proviral clone NL4-3 was obtained from AIDS
Reagent Reference Program. Vpr-deficient HIV-1 pro-
virus pNL4-3-VprX [52] and pNL101-ΔVif were
obtained from V. Planelles [42]. HIV-1 strain ΔVV was
constructed by replacing Vif open reading frame in
pNL4-3-VprX with ΔVif from pNL101-ΔVif by Nhe I-
PflM I restriction digest. CEMx174 human lymphocytes
were grown in RPMI with 10% fetal bovine serum and
1% antibiotic-antimycotic (Gibco). HEK 293 cells were
grown in DMEM with 10% fetal bovine serum and 1%
antibiotic-antimycotic (Gibco).
Transfection, infection and flow cytometry
Plasmid transfections were conducted with Fugene 6
(Roche) based on manufacturer instruction. HIV-1 vir-
ions were propagated by transfection of HEK 293 cells
with 10 μgo fH I V - 1
NL4-3 or the derivative proviruses.
Medium was replaced at 12 hours post-transfection, and
virion-containing supernatant medium was collected at
three 12 hour intervals for Gag p24 ELISA (Zeptome-
trix). CEMx174 cells (1 × 10
6) were incubated with cell-
free supernatant medium containing 3 × 10
8 pg/ml of
Gag for 48 hours. Subsequently CEMx174 lymphocytes
were infected by co-culture, which is more efficient than
infection with cell-free virus. Producer cells were iso-
lated on Ficoll and co-cultured with naive CEMx174 at
a ratio of 1:10. Progression of the infections was evalu-
ated at regular intervals by FACS of intracellular Gag.
Cells were fixed and permeabilized with Cytofix/Cyto-
perm kit (BD Biosciences) and stained with FITC-conju-
gated anti-p24 antibody (KC57-FITC, Beckman Coulter).
FACS on a BD FACSCalibur was analyzed in CellQuest
Pro (BD Biosciences).
Microarray probes, hybridization and analysis
Total RNA was isolated with Trizol reagent (Invitrogen)
and similar RNA quality and concentration were deter-
mined by Bioanalyzer (Agilent) and biotin-labeled com-
plementary DNA was generated by reverse transcription.
Hybridization was performed at Ohio State University
Comprehensive Cancer Center microarray core facility
on miRNA microarray chip OSU_CCC version 4.0 that
contains 906 human miRNA probes potted in duplicate,
with two or three independent biological replicates. The
chip captures 518 mature miRNA and 332 precursors
[53]. GenePix Pro 6 image analysis software was used to
quantify the signals detected by the array scanner. Back-
ground subtracted signal intensity was obtained for each
spot on the chip and averaged over duplicate probe sets
before log base 2 transformation. Quantile normalization
was utilized to normalize experimental variation among
chips [67]. Normalized expression values of each
m i R N Ap r o b es e tw e r ea v e r a g e do v e ra tl e a s tt w os a m -
ples of each virus infection and expression ratios were
calculated between virus infections. Blank spots on the
chip were used to evaluate the signal measurement
uncertainty. Microarray data deposited at NCBI Gene
Expression Omnibus [68] are accessible through GEO
Series accession number [GSE:21892] (http://www.ncbi.
nlm.nih.gov/geo/query/acc.cgi?acc=GSE21892). Statisti-
cal software R was employed for data manipulation.
Aggregate data was analyzed in Microsoft Excel by the
use of pivot tables. Probe expression levels were scored
as above or below minimal detectable levels (cutoff log2
= 5), and only those probes above minimal detectable
limits were used in analysis. Ratios of expression com-
pared to mock infection were calculated for each viral
infection and each miRNA probe and used to construct
scatterplots.
Reverse transcription and real-time PCR
We prepared cDNA from 10 ng total cellular RNA
using the Taqman MicroRNA Reverse Transcription kit
(Applied Biosciences) and the appropriate primer from
the Taqman MicroRNA Assay (Applied Biosciences).
According to the manufacturer’s protocol, 1.33 μLw a s
carried forward into the PCR reaction with Taqman
Universal Master Mix II (Applied Biosciences). LightCy-
cler 480 (Roche) was used to collect and analyze data.
Dilution curves were generated for each probe assayed
and used to determine probe efficiency. Efficiency-cor-
rected abundances of miR-29a, miR-128, miR-198, and
miR-214 were determined relative to internal control
snoRNA RNU48, and expression relative to mock infec-
tion was calculated using the ΔΔCT method [61].
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